January 2, 2024

Phase 1 data demonstrate that SRP-001 exhibits an exceptionally strong safety and robust pharmacokinetic profile and is well-tolerated
Well-designed Phase 2 trials set to show statistical significance compared to placebo and positive control

New Orleans, LA, January 2, 2024 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company focused on developing innovative pain treatments, announced today that it has successfully completed a Phase 1 trial (NCT05484414). The Phase 1 randomized clinical trial (RCT) of SRP-001, a first-in-class analgesic targeting the midbrain’s PAG region, was a randomized, double-blind, placebo-controlled study assessing the safety, tolerability, and pharmacokinetics (PK) of SRP-001 in healthy subjects. Conducted in collaboration with Quotient Sciences in Miami, Florida, the trial’s completion marks a significant milestone, as SRP-001 has now received U.S. FDA Fast-Track designation, underscoring its potential in the safe and effective treatment of pain.

The demand for

Read more here

November 1, 2023

South Rampart’s Global Intellectual Property Portfolio Now Includes Patents in Key Markets: United States, Europe, Greater China, India, Japan, S. Korea, Australia, Canada, Brazil, Russia, and Mexico

New Orleans, LA, November 1, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company focused on developing innovative pain treatments,

announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

The patent, entitled “Compositions and methods for ameliorating pain,” encompasses the methods and composition of matter for a library of novel non-opioid small molecules devoid of liver toxicity for acute, chronic, and neuropathic pain. This includes the Company’s lead clinical candidate, SRP-001, which the U.S. FDA granted Fast Track designation for acute pain on October 9, 2023, and is ending Phase

Read more here

Oct. 12, 2023

The Fast Track designation accelerates SRP-001’s path to U.S. FDA submission for the treatment of acute pain

Enhanced time-to-market delivers a therapeutic alternative to habit-forming opioids and acetaminophen, the leading cause of acute liver failure in the U.S.

NEW ORLEANS, Oct. 12, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage biopharmaceutical company targeting the safer treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company for SRP-001 for the treatment of acute pain. SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain’s periaqueductal grey (PAG) region without liver and kidney toxicities. The Fast Track designation facilitates the development and expedites the review of new therapies for serious conditions, aiming to bring important new drugs to patients earlier and

Read more here

October 10, 2023

 – BIO Investor Forum taking place on October 17-18, 2023 –

 – The 17^th Annual Pain Therapeutics Summit taking place on October 19-20, 2023 –

New Orleans, LA, October 10, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company developing SRP-001, a first-in-class non-opioid candidate for the treatment of chronic and acute pain, today announced the Company’s executive team will be participating in the upcoming investor events throughout October 2023:

BIO Investor Forum (San Francisco, CA):

Date: October 17-18, 2023

Corporate Presentation Time: 2:15 PM ET, Oct. 17, 2023

Title: ‘‘SRP-001, A First-in-Class, Non-Opioid Analgesic Targeting Novel Pain Signaling Pathways in the Periaqueductal Grey Region: Phase 1 Interim Results & Comparative Efficacy.”

Panel Discussion: 5:00 PM ET, Oct. 17, 2023

Title: “Succeeding at Technology Transfer:  Best Practices for Industry-Academia Collaboration.”

Program: https://bif.bio.org/program

South Rampart’s Co-founder and CEO, Dr. Hernan Bazan, will present a Corporate

Read more here

Sept. 21, 2023

The NIH’s CRP Award Further Validates the Business Case and Commercial Opportunity of
SRP-001 as a First-in-Class Non-narcotic Analgesic for Acute and Chronic Pain

NEW ORLEANS, Sept. 21, 2023 — South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that it has been awarded The Commercialization Readiness Pilot Program (CRP) grant by the National Institute of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS) for its application entitled ‘Novel non-narcotic analgesic for acute and chronic pain.’ This grant under award number 2SB1NS119103–04 propels select biotech firms towards market readiness, bolstering South Rampart’s mission to foster advancements in the safer treatment of pain management through novel non-narcotic solutions. Today’s announcement follows the Company’s earlier receipt of the NIH’s Fast-Track Small Business Technology Transfer (STTR) Commercialization

Read more here

August 22, 2023

– SRP-001, a novel, non-opioid investigational drug that avoids the liver toxicity associated with acetaminophen, positioned to address the unmet medical need for non-toxic and non-addictive acute and chronic pain therapeutics –

– Data expected in 3Q 2023 –

New Orleans, LA, Aug 22, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the first patient of its Phase 1 trial, multiple ascending dose (MAD) study, has been dosed. The primary objective of the MAD study is to assess the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of oral SRP-001 to healthy male and female volunteers, with the primary endpoints being safety and tolerability by assessing adverse events (AEs), vital signs, electrocardiograms (ECGs), physical examinations, laboratory safety tests, and select PK/PD parameters. The trial is expected to be completed in

Read more here

July 6, 2023

South Rampart’s global intellectual property portfolio now includes granted patents in the United States, China, India, Japan, Australia, Canada, Brazil, Russia, and Mexico

New Orleans, LA, July 6, 2023 – South Rampart Pharma, Inc. (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of SRP-001, South Rampart’s novel, non-opioid new chemical entity that avoids the liver toxicity associated with acetaminophen. The Company is currently developing SRP-001 for treating acute and chronic pain and is evaluating it in an ongoing Phase 1 trial. This patent, as well as other patents the Company has been granted and is currently pursuing, is a key part of South Rampart’s global intellectual property (IP) and patent strategy.

The Chinese Patent Office issued

Read more here

Jan. 31, 2023

Hernan Bazan, MD, FACS, CEO and Co-Founder, will provide a company update

Dr. Bazan will also participate in a panel on pain therapeutics innovation with a VP of Industry Research from BIO and Program Directors from NIH and the U.S. Pain Foundation

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative non-opioid medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at the BIO CEO & Investor Conference on Monday, February 6.

Dr. Bazan’s presentation will highlight the recent company developments on its novel non-opioid lead asset, ongoing pipeline progress, clinical trial updates and anticipated milestones. Details about the presentation are as follows:

Presenter: Hernan Bazan, MD, FACS,

Read more here

Oct. 21, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at Arrowhead’s 16th Annual Pain Therapeutics Summit.

Taking place in Washington, DC, on November 14-15, 2022, the Pain Therapeutics Summit is the US’s premier conference covering pain research and emerging therapeutics. Leaders from the biopharmaceutical industry, academia, and the NIH attend the conference to learn about the latest advances in treating various kinds of pain and network with colleagues from industry, academia, clinical research organizations, and government.

Dr. Bazan’s presentation, “Overcoming the Liver Toxicity Associated with Acetaminophen Via a New Class of Small Molecule Non-Opioids,” will highlight the ongoing clinical development of novel non-opioid small molecule SRP-001 for the treatment

Read more here

Oct. 4, 2022

– New patent grant further secures South Rampart’s competitive position in next-generation and disruptive investigational drugs for acute pain –

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain, today announced the issuance of a composition of matter US patent No. 11,458,142 for its novel, non-opioid, and non-liver toxic treatments for pain. The issued patent covers a library of novel small molecules, including the Company’s lead program, SRP-001, which is currently being studied in a two-part randomized, double-blind, placebo-controlled study Phase 1 study evaluating safety, tolerability, and pharmacokinetics, with data expected early in 2023.

This issued patent adds to the Company’s growing patent portfolio, which includes ‘Compositions and methods for ameliorating pain and reducing fever’ US patent No. 11,007,199. The Composition of Matter patent issued today has been nationalized in key world markets. South

Read more here

Sept. 22, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that it received a Notice of Award from the National Institutes of Health (NIH) regarding Year 3 of its Small Business Technology Transfer (STTR) grant.

The NIH grant is entitled ‘Novel non-narcotic analgesic for acute and chronic pain.’ South Rampart Pharma will receive the Year 3 incremental Award of the $1.9M grant administered through the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), which will continue to help support the development of SRP-001, the Company’s lead drug candidate.

SRP-001 is a novel, non-opioid small molecule with the potential to overcome many risks associated with current pain medicines, including the liver toxicity of acetaminophen. Importantly, SRP-001 mirrors acetaminophen’s clinically validated mechanism of action while simultaneously muting the biological activity that causes liver toxicity. South Rampart Pharma is

Read more here

Aug. 25, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that the Company will present a late-breaking abstract at the International Association for the Study of Pain (IASP) 2022 World Congress on Pain, which will take place on September 20-23, 2022, in Toronto, Canada.

The late-breaking presentation, entitled “Novel Non-Opioid Analgesic for Acute and Chronic Pain: From Discovery to Phase 1 Trial,” will chronicle the invention and development of SRP-001 (previously known as SRP-3D (DA)). Central to SRP-001’s therapeutic differentiation, this non-opioid investigational pain medication exhibits comparable, if not better, efficacy as similar approved drugs but notably does not exhibit their liver or kidney toxicity. South Rampart’s CEO and Co-founder, Hernan Bazan, MD, FACS, will deliver the presentation.

“I’m delighted to have this opportunity to showcase the groundbreaking work we’ve done with SRP-001,” commented Dr. Bazan. “Liver toxicity

Read more here

Aug. 16, 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced the appointment of Josh Blacher as the company’s Chief Financial Officer. In this capacity, Mr. Blacher will be responsible for the Company’s finance and accounting department, as well as launch a robust corporate development effort.

Mr. Blacher brings to South Rampart Pharma over twenty years of leadership experience in senior positions in the healthcare and capital markets sectors. Hernan Bazan, M.D., F.A.C.S., CEO and Co-Founder of South Rampart Pharma and The Endowed John Ochsner Professor of Surgery at the Ochsner Clinic, commented, “We are thrilled to welcome Josh to our team. Josh brings us a valuable combination of executing growth capital initiatives as well as strategic collaborations with biopharmaceutical partners.” Dr. Bazan continued, “As we ready for Phase 2 clinical trials of our novel non-opioid

Read more here

May 4, 2022

$1.9 million NIH fast-track STTR grant fuels next stage of clinical program dedicated to the development of a novel non-opioid approach to pain management

Lead program SRP-3D (DA) advances in ongoing Phase 1 clinical trial with data expected in the third quarter of 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced it achieved milestones outlined in the Phase I portion of its Small Business Technology Transfer (STTR) grant (1R42NS119103) received from the National Institutes of Health (NIH) and advanced to the Phase II portion of its NIH grant. The ‘fast-track’ combined Phase I/II award provides for $1.9 million of funding to support the ongoing clinical development of the Company’s lead small molecule, SRP-3D (DA), a novel non-opioid therapeutic candidate. South Rampart Pharma currently is completing the single

Read more here

March 23, 2022

SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications

Potential to address the significant unmet need for new, safe, effective, and non-opioid pain medications

Development program funded by the National Institutes of Health (NIH) through a Small Business Technology Transfer (STTR) Fast Track Grant

Topline results expected Q3 2022

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company focused on advancing innovative medications for the treatment of pain and fever, announced today patient enrollment and dosing in its Phase 1 study evaluating SRP-3D (DA) for pain is underway.

“We are committed to improving the lives of people suffering from acute, chronic, or neuropathic pain by developing a new class of small molecule, non-opioid pain medicines. To date, SRP-3D (DA) has shown promising efficacy in reducing both pain and fever while lacking the liver and kidney toxicity associated

Read more here

Sep 25, 2020

The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer (STTR) grant to South Rampart Pharma. The New Orleans life science company is developing a new class of non-opioid medicines to relieve pain and reduce fever discovered at and licensed from LSU Health New Orleans, its formal collaborating research institution.

The grant will fund late-stage, pre-clinical development of the new analgesic/antipyretic and will also support continued collaboration with LSU Health New Orleans Neuroscience Center of Excellence on pain mechanisms. A paper describing the patented new drug was recently published in the European Journal of Medicinal Chemistry.

“The safe treatment of acute and chronic pain is one of the most prevalent and costly public health issues worldwide,” said Hernan Bazan, MD, DFSVS, FACS, CEO and co-founder of South Rampart Pharma, and Professor of Surgery at the Ochsner

Read more here

July 10, 2020

South Rampart Pharma, LLC (“South Rampart” or “the Company”), a company committed to improving the lives of people suffering from pain by developing a new class of non-opioid pain medicines, today announced a peer-reviewed publication detailing the identification and characterization of a new class of compounds able to reduce pain and fever without abuse potential or the liver and kidney toxicity associated with over the counter pain medicines such as acetaminophen. The paper, published in the European Journal of Medicinal Chemistry, is available as open access and entitled, “A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis¹.”

“We are currently working to finalize the preclinical data package necessary to submit our lead molecule for the first Investigational New Drug (IND) application by the third quarter of 2020, followed by the rapid initiation of Phase 1 clinical trials to evaluate safety. Ongoing preclinical studies have

Read more here

Jul 6, 2020

Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage to the liver or kidneys. The research is published online in the European Journal of Medicinal Chemistry.

Current drugs have unwanted side effects. Opioids can not only cause addiction; recent studies have shown they can be no more effective at relieving pain than non-narcotic drugs. Non-steroidal anti-inflammatories (NSAIDs) can cause kidney damage. Acetaminophen is an effective drug, but overuse can result in liver damage.

The research team, led by Drs. Hernan A. Bazan, a professor in the Department of Surgery and Program Director of the Vascular Surgery Fellowship at Ochsner Clinic, and Surjyadipta Bhattacharjee, a post-doctoral researcher at the LSU Health New Orleans Neuroscience Center of Excellence, set out to discover what causes the liver damage associated with

Read more here